Barbara Weber, M.D., has been the CEO of Tango Therapeutics since March 2017. With an M.D. from a top medical school, her background is solid in medicine, specifically in oncology and drug development. Before Tango, she held significant roles at...
Barbara Weber, M.D., has been the CEO of Tango Therapeutics since March 2017. With an M.D. from a top medical school, her background is solid in medicine, specifically in oncology and drug development. Before Tango, she held significant roles at major pharmaceutical companies like Novartis and GlaxoSmithKline, where she was part of teams that pushed boundaries in cancer research. Under her leadership, Tango has focused on developing novel cancer treatments using innovative approaches like synthetic lethality. Dr. Weber's vision is clear: tackle the genetic complexities of cancer to improve patient lives. Her management style has led to key advancements in the company’s clinical trials and a strong research team. In 2023, her total compensation was about $3.4 million, including a performance-based bonus reflecting the company's achievements. Interestingly, she is a Venture Partner at Third Rock Ventures, which suggests her insights in biotech extend beyond her CEO role. Known for her hands-on approach, she actively monitors performance metrics to align company goals with employee incentives. Her insider trading activity shows a mix of buying and selling stocks, indicating strategic financial management. Dr. Weber is not just leading a company; she's on a mission to change how we understand and treat cancer. Her strategy combines science, leadership, and a commitment to innovation, shaping the future of healthcare.